1584 related articles for article (PubMed ID: 26485757)
1. Treatment outcomes and late toxicities of 869 patients with nasopharyngeal carcinoma treated with definitive intensity modulated radiation therapy: new insight into the value of total dose of cisplatin and radiation boost.
Ou X; Zhou X; Shi Q; Xing X; Yang Y; Xu T; Shen C; Wang X; He X; Kong L; Ying H; Hu C
Oncotarget; 2015 Nov; 6(35):38381-97. PubMed ID: 26485757
[TBL] [Abstract][Full Text] [Related]
2. Concurrent chemoradiotherapy in locoregionally advanced nasopharyngeal carcinoma: treatment outcomes of a prospective, multicentric clinical study.
Wu F; Wang R; Lu H; Wei B; Feng G; Li G; Liu M; Yan H; Zhu J; Zhang Y; Hu K
Radiother Oncol; 2014 Jul; 112(1):106-11. PubMed ID: 24933452
[TBL] [Abstract][Full Text] [Related]
3. Neoadjuvant chemotherapy plus intensity-modulated radiotherapy versus concurrent chemoradiotherapy plus adjuvant chemotherapy for the treatment of locoregionally advanced nasopharyngeal carcinoma: a retrospective controlled study.
Qiu WZ; Huang PY; Shi JL; Xia HQ; Zhao C; Cao KJ
Chin J Cancer; 2016 Jan; 35():2. PubMed ID: 26739148
[TBL] [Abstract][Full Text] [Related]
4. T4/N2 classification nasopharyngeal carcinoma benefit from concurrent chemotherapy in the era of intensity-modulated radiotherapy.
Xie R; Xia B; Zhang X; Hu W; Zhao R; Xie C; Wang J; Zhang N; Wu S
Oncotarget; 2016 Dec; 7(49):81918-81925. PubMed ID: 27636993
[TBL] [Abstract][Full Text] [Related]
5. Pretreatment prognostic factors of survival and late toxicities for patients with nasopharyngeal carcinoma treated by simultaneous integrated boost intensity-modulated radiotherapy.
Lin YH; Huang TL; Chien CY; Chen HC; Hsu HC; Huang EY; Wang CJ; Huang YJ; Wang YM; Huang CC; Chou SY; Liao KC; Fang FM
Radiat Oncol; 2018 Mar; 13(1):45. PubMed ID: 29554940
[TBL] [Abstract][Full Text] [Related]
6. Long-term outcomes of concurrent chemoradiotherapy versus radiotherapy alone in stage II nasopharyngeal carcinoma treated with IMRT: a retrospective study.
Su Z; Mao YP; Tang J; Lan XW; OuYang PY; Xie FY
Tumour Biol; 2016 Apr; 37(4):4429-38. PubMed ID: 26499947
[TBL] [Abstract][Full Text] [Related]
7. Definitive intensity-modulated radiation therapy for nasopharyngeal carcinoma: long-term outcome of a multicenter prospective study.
Wang R; Wu F; Lu H; Wei B; Feng G; Li G; Liu M; Yan H; Zhu J; Zhang Y; Hu K
J Cancer Res Clin Oncol; 2013 Jan; 139(1):139-45. PubMed ID: 22986812
[TBL] [Abstract][Full Text] [Related]
8. Long-term outcomes of early-stage nasopharyngeal carcinoma patients treated with intensity-modulated radiotherapy alone.
Su SF; Han F; Zhao C; Chen CY; Xiao WW; Li JX; Lu TX
Int J Radiat Oncol Biol Phys; 2012 Jan; 82(1):327-33. PubMed ID: 21035959
[TBL] [Abstract][Full Text] [Related]
9. Retrospective Analysis of the Survival Benefit of Induction Chemotherapy in Stage IVa-b Nasopharyngeal Carcinoma.
Lan XW; Zou XB; Xiao Y; Tang J; OuYang PY; Su Z; Xie FY
PLoS One; 2016; 11(8):e0160758. PubMed ID: 27509025
[TBL] [Abstract][Full Text] [Related]
10. Long-term outcomes of intensity-modulated radiotherapy for 868 patients with nasopharyngeal carcinoma: an analysis of survival and treatment toxicities.
Sun X; Su S; Chen C; Han F; Zhao C; Xiao W; Deng X; Huang S; Lin C; Lu T
Radiother Oncol; 2014 Mar; 110(3):398-403. PubMed ID: 24231245
[TBL] [Abstract][Full Text] [Related]
11. Prognostic factors of 305 nasopharyngeal carcinoma patients treated with intensity-modulated radiotherapy.
Han L; Lin SJ; Pan JJ; Chen CB; Zhang Y; Zhang XC; Liao XY; Chen QS
Chin J Cancer; 2010 Feb; 29(2):145-50. PubMed ID: 20109341
[TBL] [Abstract][Full Text] [Related]
12. Survival of stage II nasopharyngeal carcinoma patients with or without concurrent chemotherapy: A propensity score matching study.
Liu DH; Zhou XY; Pan YG; Chen S; Ye ZH; Chen GD
Cancer Med; 2020 Feb; 9(4):1287-1297. PubMed ID: 31859464
[TBL] [Abstract][Full Text] [Related]
13. Intensity-modulated radiotherapy with simultaneous integrated boost for locoregionally advanced nasopharyngeal carcinoma.
Yi J; Huang X; Gao L; Luo J; Zhang S; Wang K; Qu Y; Xiao J; Xu G
Radiat Oncol; 2014 Feb; 9():56. PubMed ID: 24533569
[TBL] [Abstract][Full Text] [Related]
14. Long-term outcome and late toxicities of simultaneous integrated boost-intensity modulated radiotherapy in pediatric and adolescent nasopharyngeal carcinoma.
Tao CJ; Liu X; Tang LL; Mao YP; Chen L; Li WF; Yu XL; Liu LZ; Zhang R; Lin AH; Ma J; Sun Y
Chin J Cancer; 2013 Oct; 32(10):525-32. PubMed ID: 24016394
[TBL] [Abstract][Full Text] [Related]
15. The value of the Prognostic Nutritional Index (PNI) in predicting outcomes and guiding the treatment strategy of nasopharyngeal carcinoma (NPC) patients receiving intensity-modulated radiotherapy (IMRT) with or without chemotherapy.
Miao J; Xiao W; Wang L; Han F; Wu H; Deng X; Guo X; Zhao C
J Cancer Res Clin Oncol; 2017 Jul; 143(7):1263-1273. PubMed ID: 28247035
[TBL] [Abstract][Full Text] [Related]
16. The prognostic factors for locally advanced cervical cancer patients treated by intensity-modulated radiation therapy with concurrent chemotherapy.
Chen CC; Wang L; Lin JC; Jan JS
J Formos Med Assoc; 2015 Mar; 114(3):231-7. PubMed ID: 25777974
[TBL] [Abstract][Full Text] [Related]
17. Long-term survival and late complications of intensity-modulated radiotherapy for recurrent nasopharyngeal carcinoma.
Kong F; Zhou J; Du C; He X; Kong L; Hu C; Ying H
BMC Cancer; 2018 Nov; 18(1):1139. PubMed ID: 30453915
[TBL] [Abstract][Full Text] [Related]
18. Mixed-beam approach in locally advanced nasopharyngeal carcinoma: IMRT followed by proton therapy boost versus IMRT-only. Evaluation of toxicity and efficacy.
Alterio D; D'Ippolito E; Vischioni B; Fossati P; Gandini S; Bonora M; Ronchi S; Vitolo V; Mastella E; Magro G; Franco P; Ricardi U; Krengli M; Ivaldi G; Ferrari A; Fanetti G; Comi S; Tagliabue M; Verri E; Ricotti R; Ciardo D; Jereczek-Fossa BA; Valvo F; Orecchia R
Acta Oncol; 2020 May; 59(5):541-548. PubMed ID: 32090645
[No Abstract] [Full Text] [Related]
19. Combined prognostic value of pretreatment anemia and cervical node necrosis in patients with nasopharyngeal carcinoma receiving intensity-modulated radiotherapy: A large-scale retrospective study.
Zhang LL; Zhou GQ; Li YY; Tang LL; Mao YP; Lin AH; Ma J; Qi ZY; Sun Y
Cancer Med; 2017 Dec; 6(12):2822-2831. PubMed ID: 29034992
[TBL] [Abstract][Full Text] [Related]
20. Propensity score matching analysis of cisplatin-based concurrent chemotherapy in low risk nasopharyngeal carcinoma in the intensity-modulated radiotherapy era.
Zhang LN; Gao YH; Lan XW; Tang J; Su Z; Ma J; Deng W; OuYang PY; Xie FY
Oncotarget; 2015 Dec; 6(41):44019-29. PubMed ID: 26528755
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
